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Late-stage disease at presentation to an HIV clinic in 
eastern Tanzania: A retrospective cross-sectional study
                         Abstract
Background
Late presentation and delayed treatment initiation is associated with poor 
outcomes in patients with HIV. Little is known about the stage at which 
HIV patients present at HIV clinics in Tanzania.
Aim: 
This study aimed at determining the proportion of HIV patients presenting 
with WHO clinical stages 3 and 4 disease, and the level of immunity at the 
time of enrollment at the care and treatment center.
Methods
A retrospective cross-sectional study was conducted among 366 HIV-
infected adults attending HIV clinic at Mwananyamala Hospital in Dar es 
Salaam, Tanzania. Data were obtained from the care and treatment clinic 
database.
Results
Late stage disease at the time of presentation was found in 276 (75.4%) 
of the patients; out of whom 153 (41.8%) presented with CD4 count 
<200 cells/ul and 229 (62.6%) presented with WHO clinical stage 3 or 4 
at the time of clinic enrollment. Strategies to improve early diagnosis and 
treatment initiation should be improved.
Introduction
Existing evidence shows that treatment outcomes in HIV 
patients are related to patient health status at the time of  ART 
initiation. Good treatment outcomes have been associated 
with early initiation of  treatment. Delayed initiation of  ART 
has been associated with increased morbidity and mortality1 
impaired immune recovery2 increased financial strain on the 
health care system,3 and an increased risk of  transmission of  
the disease4.
Several reports from developed countries have shown that 
a relatively large percent of  people with HIV present late 
for HIV care and treatment5. There is limited published 
data on HIV stage at presentation among sub-Saharan 
African patients. Little is known about the proportion 
and characteristics of  patients presenting to HIV care and 
treatment clinics in the later stages of  the disease. Most 
reports in sub-Saharan Africa focus on the CD4 count at 
ART initiation and reveal that a majority of  patients initiate 
ART at low CD4 levels6. This study aimed at determining the 
proportion of  HIV patients presenting with WHO clinical 
stages 3 and 4 disease, and the level of  immunity at the 
time of  enrollment at the HIV care and treatment center at 
Mwananyamala Hospital in Dar es Salaam, Tanzania.
Methods 
Study design, setting, and participants
A clinic-based retrospective cross-sectional study was 
conducted among HIV-infected adults attending the care and 
treatment clinic at Mwananyamala Hospital, between January 
and December 2013. Mwananyamala Hospital is a regional 
referral hospital, located in Kinondoni District, Dar es 
Salaam, Tanzania. It caters to a population of  approximately 
1.5 million people. The HIV care and treatment clinic has a 
total of  28,000 clients, of  whom 10,500 are on ART. 
Sample size and sampling procedure
The sample size was obtained using the formula for single 
population proportion. In order to get a representative 
sample, a systematic sampling procedure was used to 
select the study participants from the sampling list, which 
contained a total of  9164 patients attending HIV clinic in 
the year 2013. This total number of  patients was divided by 
the sample size required in order to calculate the sampling 
intervals (k = 25). If  a selected participant had missing data, 
the next patient was selected instead.
Data collection
A specially designed data collection tool was used for 
recording the demographic data, clinical characteristics, and 




WHO clinical stage and the CD4 cell count at the time of  
enrollment were used as the outcome variable for this analysis. 
The WHO clinical stages were categorized for each patient 
dichotomously as severe (stage 3 and 4) or not severe (stage 
1 and 2). CD4 cell count recordings were also dichotomized, 
as either < 200 cells/mm3 or ≥ 200 cells/mm3. The timing 
of  patient presentation was considered late or early: those 
patients presenting with either HIV WHO clinical stage 3 or 
4 or CD4 < 200 cells/mm3 were defined as late presenters.
Independent variables
Independent variables included the sociodemographic 
information recorded in the database, including the age, 
gender, and marital status.
Statistical analysis
Continuous variables were summarized by medians and 
interquartile ranges (IQRs), and categorical variables were 
summarized by frequencies and percentages. Data were 
analyzed using Stata/IC version 10.1 (College Station, Texas, 
USA). The presentation was dichotomized, so that those 
with WHO clinical stage 3 or 4 disease or a CD4 count < 200 
cells/mm3 were considered late presenters for the analysis, 
and those with stage 1 or 2 disease or a CD4 count ≥ 200 
cells/mm3 were considered early presenters.
Ethical considerations
The study was approved by the Institutional Ethics Review 
Board of  the University of  Dodoma. Permission to conduct 
the study was also granted by the district medical officer and 
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the medical officer in charge of  Mwananyamala Hospital.
Results 
Study population and patient characteristics
A total of  366 patients participated in this study. Out of  
these, 235 (64.2%) were females and 131 (35.8%) were males. 
The median age of  the study participants was 36 years (IQR 
30-43) and the median CD4 count at the time of  enrolment 
to the clinic was 202.5 cells/mm3 (IQR 104-300). Out of  
the 366 study participants, 160 (43.7%) were married, 130 
(35.5%) were single, 32 (8.7%) were widows or widowers, 26 
(7.1%) were divorced, and 18 (4.9%) were cohabiting (Table 
1). 
Stage of disease and level of immunity at clinic 
enrolment
At the time of  enrolment to the clinic, 276 patients (75.4%) 
had late-stage disease. Out of  these, 196 patients (53.6%) 
met WHO clinical stage 3 criteria and 33 patients (9.0%) 
had WHO clinical stage 4 disease. In terms of  the level of  
immunity, 153 patients (41.8%) were enroled with a CD4 cell 
count < 200 cells/mm3, 76 patients (20.8%) with a CD4 
count between 200 and 350 cells/mm3, and 75 patients 
(20.5%) with a CD4 count between 351 and 500 cells/mm3. 
Only 62 patients (16.9%) were enroled at the clinic with a 
CD4 count of  ≥ 500 cells/mm3 (Table 1).
Discussion
In this study, the majority of  participants were late presenters. 
The proportion of  those presenting at clinical stage 3 or 4 
is slightly higher than a study done in Uganda, which found 
that 40% of  the patients were enroled with a WHO clinical 
stage 3 or 4 designation6. Several other studies have also 
shown that the majority of  patients in sub-Saharan Africa 
are diagnosed and enroled in care and treatment services 
with low CD4 counts7.
Reports of  the trends regarding late presentation in sub-
Saharan Africa show that efforts focused on increasing HIV 
testing coverage have had positive effects, as the proportion 
of  late presentation has been decreasing5. Low risk of  
late presentation was associated with enrolment through 
prevention of  mother-to-child transmission (PMTCT) 
protocols and residing in a region with wide coverage of  
HIV testing5. Emphasis on male involvement in PMTCT can 
also increase early testing for HIV.8.
Late presentation has been shown to impose a number 
of  challenges in the management of  HIV patients. It is 
often associated with mortality, either before or after ART 
initiation9. Very low CD4 counts at the time of  ART initiation 
(< 200 cells/mm3) has been associated with increased risk of  
acquiring one or more opportunistic infections; this increases 
the risk of  developing immune reconstitution inflammatory 
syndrome after ART initiation10. It also increases the risk of  
incomplete immune recovery. 
Table 1: Baseline sociodemographic and clinical characteristics of HIV-infected patients attending Mwananyamala Care and Treatment Clinic, 
January to December 2013 (n=366)
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In our study, the median CD4 count at the time of  ART 
initiation was 202.5 cells/mm3; 153 of  our study subjects 
(41.8%) started ART with CD4 < 200 cells/ul. This study 
had several limitations. It was a cross-sectional study and is 
prone to selection bias. This was a sample of  clinic attendees 
only. The analyzed late presentation may not truly represent 
patients who have never attended the clinic. The data used 
for this analysis comes from the records of  routine clinic 
encounters, which lack some important variables that could 
have been used to assess other possible predictors of  late 
presentation. In addition, the analysis was based on a single 
clinic; therefore, results may not be generalizable. The high 
percentage of  late-stage disease and late presenters found in 
this study suggests possible barriers to HIV care in Tanzania. 
Late presentation reduces the benefits of  ART, increases 
the chances of  continuing HIV transmission, and increases 
the costs of  medical care. This study highlights the need to 
develop and implement strategies that will facilitate early 
diagnosis and entry into HIV care.
Conclusion
Despite ongoing efforts to increase HIV testing coverage in 
Tanzania, late-stage disease at the time of  enrolment is still 
high. The majority of  patients are still enroled with WHO 
clinical stage 3 or 4 disease or with a CD4 count < 200 cells/
mm3. There is a need to develop and implement strategies 
that will further increase HIV testing coverage and improve 
the number of  patients who are diagnosed and enroled in 
HIV care early, in order to ensure better treatment outcomes.
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